Syngene International Limited (SYNGENE.NS)
INR 727.0
(-0.29%)
INR 727.0
(-0.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 61.51 Billion INR | 5.5% |
| 2022 | 58.31 Billion INR | 4.8% |
| 2021 | 55.63 Billion INR | 13.94% |
| 2020 | 48.83 Billion INR | 17.3% |
| 2019 | 41.62 Billion INR | 12.4% |
| 2018 | 37.03 Billion INR | 16.13% |
| 2017 | 31.89 Billion INR | 14.97% |
| 2016 | 27.73 Billion INR | 16.08% |
| 2015 | 23.89 Billion INR | 68.1% |
| 2014 | 14.21 Billion INR | 19.36% |
| 2013 | 11.9 Billion INR | 64.44% |
| 2012 | 7.24 Billion INR | 23.46% |
| 2011 | 5.86 Billion INR | 16.37% |
| 2010 | 5.04 Billion INR | -1.54% |
| 2009 | 5.12 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 61.11 Billion INR | -0.65% |
| 2024 Q2 | 61.36 Billion INR | 0.4% |
| 2023 Q4 | 61.51 Billion INR | 7.62% |
| 2023 Q1 | 60.61 Billion INR | 3.94% |
| 2023 Q2 | 58.46 Billion INR | -3.54% |
| 2023 Q3 | 57.16 Billion INR | -2.23% |
| 2023 FY | 61.51 Billion INR | 5.5% |
| 2022 Q3 | 54.93 Billion INR | 2.08% |
| 2022 Q4 | 58.31 Billion INR | 6.15% |
| 2022 FY | 58.31 Billion INR | 4.8% |
| 2022 Q1 | 54 Billion INR | -2.93% |
| 2022 Q2 | 53.81 Billion INR | -0.36% |
| 2021 FY | 55.63 Billion INR | 13.94% |
| 2021 Q2 | 48.57 Billion INR | -2.48% |
| 2021 Q4 | 55.63 Billion INR | 13.12% |
| 2021 Q3 | 49.18 Billion INR | 1.26% |
| 2021 Q1 | 49.8 Billion INR | 2.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 48.83 Billion INR | 17.3% |
| 2020 Q2 | 44.85 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 48.83 Billion INR | 0.0% |
| 2019 Q4 | 41.62 Billion INR | 0.0% |
| 2019 FY | 41.62 Billion INR | 12.4% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 39.55 Billion INR | 0.0% |
| 2018 FY | 37.03 Billion INR | 16.13% |
| 2018 Q2 | 32.98 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 37.03 Billion INR | 0.0% |
| 2017 Q4 | 31.89 Billion INR | 11.54% |
| 2017 Q2 | 27.71 Billion INR | 0.0% |
| 2017 FY | 31.89 Billion INR | 14.97% |
| 2017 Q3 | 28.59 Billion INR | 3.18% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 25.29 Billion INR | 0.0% |
| 2016 FY | 27.73 Billion INR | 16.08% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 27.73 Billion INR | 0.0% |
| 2015 FY | 23.89 Billion INR | 68.1% |
| 2015 Q3 | 14.83 Billion INR | 1.19% |
| 2015 Q2 | 14.65 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 23.89 Billion INR | 61.13% |
| 2014 Q4 | 14.21 Billion INR | 13.36% |
| 2014 FY | 14.21 Billion INR | 19.36% |
| 2014 Q1 | - INR | 0.0% |
| 2014 Q3 | 12.54 Billion INR | 0.0% |
| 2013 FY | 11.9 Billion INR | 64.44% |
| 2012 FY | 7.24 Billion INR | 23.46% |
| 2011 FY | 5.86 Billion INR | 16.37% |
| 2010 FY | 5.04 Billion INR | -1.54% |
| 2009 FY | 5.12 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Biocon Limited | 560.7 Billion INR | 89.029% |
| Blue Jet Healthcare Limited | 10.58 Billion INR | -480.972% |
| Concord Biotech Limited | 17 Billion INR | -261.708% |
| Dishman Carbogen Amcis Limited | 95.81 Billion INR | 35.797% |
| Jubilant Ingrevia Limited | 47.31 Billion INR | -30.003% |
| Lyka Labs Limited | 1.56 Billion INR | -3825.109% |
| Panacea Biotec Limited | 12.4 Billion INR | -395.825% |
| Piramal Pharma Limited | 153.11 Billion INR | 59.824% |
| SMS Lifesciences India Limited | 3.9 Billion INR | -1475.236% |
| Supriya Lifescience Limited | 9.21 Billion INR | -567.754% |
| TAKE Solutions Limited | 881.05 Million INR | -6882.124% |
| Zota Health Care Limited | 2.28 Billion INR | -2594.188% |